BioLargo director paid $18,750 in fees via stock option grant

BioLargo, Inc. director compensation included an equity component for the most recently completed quarterly period.

Rhea-AI Filing Summary

BioLargo, Inc. director compensation included an equity component for the most recently completed quarterly period. On 12/31/2025, the reporting person received an option to purchase 101,736 shares of common stock at an exercise price of $0.1843 per share. This option was issued in lieu of $18,750 in board fees owed, under BioLargo’s 2024 Equity Incentive Plan.

Following this grant, the reporting person beneficially owned 1,265,761 derivative securities, reported as held directly. The filing indicates the person’s role as a director and that the report is filed for a single reporting person.

Insider Trade Summary

Grant/Award: 101,736 shares

Grant/Award 1 txn

Insider Park Linda

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	101,736	$0.00	$0.00

Holdings After Transaction: Option to Purchase Common Stock — 1,265,761 contracts (Direct)

Footnotes (1)

1. F1. This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioLargo (BLGO) report in this Form 4?

The report shows a director received an option to purchase 101,736 shares of BioLargo common stock on 12/31/2025, as part of board compensation.

What was the exercise price of the stock option granted to the BioLargo (BLGO) director?

The option has an exercise price of $0.1843 per share for BioLargo common stock.

What cash amount did the BioLargo (BLGO) option grant replace in director fees?

The option was issued as payment for $18,750 in fees due to the director for services on BioLargo’s board for the most recently completed quarterly period.

Under which plan was the BioLargo (BLGO) director stock option issued?

The option was granted pursuant to BioLargo’s 2024 Equity Incentive Plan.

How many derivative securities does the BioLargo (BLGO) director beneficially own after this transaction?

After the reported grant, the director beneficially owned 1,265,761 derivative securities, held directly.

What is the relationship of the reporting person to BioLargo (BLGO)?

The reporting person is identified as a director of BioLargo, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/05/2026 - 05:01 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Park Linda

(Last) (First) (Middle)

14921 CHESTNUT ST.

(Street)

WESTMINSTER CA 92683

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLARGO, INC. [ BLGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.1843	12/31/2025		A		101,736		12/31/2025	12/31/2035	Common Stock	101,736	(1)	1,265,761	D

Explanation of Responses:

1. This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan.

	/s/ John R. Browning, attorney-in-fact	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.